Recommending defunct therapies is a safety risk for hemophilia.
作者信息
Pierce Glenn F, O'Mahony Brian, Kaczmarek Radoslaw, Mekhuzla Salome, Skinner Mark W
机构信息
World Federation of Hemophilia, Montreal, Canada.
Irish Hemophilia Society, Dublin, Ireland and Trinity College, Dublin, Ireland.
出版信息
Blood Transfus. 2025 Mar;23(2):189-190. doi: 10.2450/BloodTransfus.982. Epub 2025 Jan 21.
Abstract
摘要
相似文献
1
Recommending defunct therapies is a safety risk for hemophilia.推荐已废止的疗法对血友病患者而言存在安全风险。
Blood Transfus. 2025 Mar;23(2):189-190. doi: 10.2450/BloodTransfus.982. Epub 2025 Jan 21.
2
Loss of shaker K channel conductance in 0 K+ solutions: role of the voltage sensor.在零钾离子溶液中震颤钾通道电导的丧失：电压感受器的作用
Biophys J. 1998 Oct;75(4):1828-35. doi: 10.1016/S0006-3495(98)77624-6.
3
Dilated and defunct K channels in the absence of K+.在没有钾离子的情况下扩张且失去功能的钾通道。
Biophys J. 2001 Jun;80(6):2704-14. doi: 10.1016/S0006-3495(01)76239-X.
4
Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel.了解无抑制剂的甲型血友病预防治疗覆盖政策的演变：支付方德尔菲小组。
J Manag Care Spec Pharm. 2021 Aug;27(8):996-1008. doi: 10.18553/jmcp.2021.20600. Epub 2021 Apr 12.
5
Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A.专家意见：当前和未来预防疗法旨在提高血友病 A 患者的保护水平。
J Med Life. 2022 Apr;15(4):570-578. doi: 10.25122/jml-2022-0103.
6
Antithrombotic Therapy in People with Hemophilia-A Narrative Review.
Thromb Haemost. 2025 Mar 28. doi: 10.1055/a-2548-4192.
7
Methodological quality and recommendations of hemophilia clinical practice guidelines: A scoping review.血友病临床实践指南的方法学质量与建议：一项范围综述
Health Sci Rep. 2023 Jul 13;6(7):e1326. doi: 10.1002/hsr2.1326. eCollection 2023 Jul.
8
Hemophilia A gene therapy: current and next-generation approaches.血友病 A 基因治疗：当前和下一代方法。
Expert Opin Biol Ther. 2022 Sep;22(9):1099-1115. doi: 10.1080/14712598.2022.2002842. Epub 2022 Jan 6.
9
A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B.A型和 B 型血友病基因治疗的成本效益分析的系统评价。
J Manag Care Spec Pharm. 2024 Oct;30(10):1178-1188. doi: 10.18553/jmcp.2024.30.10.1178.
10
Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics.血友病治疗创新之路上的减速带应对策略
Hemasphere. 2018 Oct;2(5):e144. doi: 10.1097/HS9.0000000000000144. Epub 2018 Oct 2.
引用本文的文献
1
Response to comments on inclusion of cryoprecipitate, pathogen-reduced on the WHO model lists of essential medicines for adults and children: a call for action.关于将去病原体冷沉淀纳入世界卫生组织成人及儿童基本药物示范清单的评论回复：行动呼吁。
Blood Transfus. 2025 Mar;23(2):191-192. doi: 10.2450/BloodTransfus.1005. Epub 2025 Jan 21.
本文引用的文献
1
Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List.2023年世界卫生组织基本药物清单对血友病患者造成伤害的风险。
Lancet Haematol. 2024 Sep;11(9):e638-e640. doi: 10.1016/S2352-3026(24)00223-0. Epub 2024 Aug 5.
2
Inclusion of cryoprecipitate, pathogen-reduced, in the WHO model lists of essential medicines for adults and children: a call for action.将经病原体灭活的冷沉淀纳入世界卫生组织成人及儿童基本药物示范清单：行动呼吁。
Blood Transfus. 2024 Nov;22(6):481-483. doi: 10.2450/BloodTransfus.687. Epub 2024 Jan 31.
3
WFH Guidelines for the Management of Hemophilia, 3rd edition.《血友病管理的居家指南》第三版
Haemophilia. 2020 Aug;26 Suppl 6:1-158. doi: 10.1111/hae.14046. Epub 2020 Aug 3.
4
Achieving the unimaginable: Health equity in haemophilia.实现难以想象的目标：血友病中的健康公平。
Haemophilia. 2020 Jan;26(1):17-24. doi: 10.1111/hae.13862. Epub 2019 Nov 13.
Zotero 插件